

Brooke E Nichols

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9422945/publications.pdf>

Version: 2024-02-01

64
papers

1,628
citations

411340

20
h-index

388640

36
g-index

80
all docs

80
docs citations

80
times ranked

2422
citing authors

#	ARTICLE	IF	CITATIONS
1	Contribution of Reinfection to Annual Rate of Tuberculosis Infection (ARI) and Incidence of Tuberculosis Disease. <i>Clinical Infectious Diseases</i> , 2023, 76, e965-e972.	2.9	4
2	Perspectives on the use of modelling and economic analysis to guide HIV programmes in sub-Saharan Africa. <i>Lancet HIV</i> , 2022, 9, e517-e520.	2.1	3
3	Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study. <i>Lancet HIV</i> , 2022, 9, e353-e362.	2.1	19
4	Optimal use of COVID-19 Ag-RDT screening at border crossings to prevent community transmission: A modeling analysis. <i>PLOS Global Public Health</i> , 2022, 2, e0000086.	0.5	0
5	The Role of Remdesivir in South Africa: Preventing COVID-19 Deaths Through Increasing Intensive Care Unit Capacity. <i>Clinical Infectious Diseases</i> , 2021, 72, 1642-1644.	2.9	14
6	Community-based delivery of HIV treatment in Zambia: costs and outcomes. <i>Aids</i> , 2021, 35, 299-306.	1.0	33
7	Economic evaluation of differentiated service delivery models for HIV treatment in Lesotho: costs to providers and patients. <i>Journal of the International AIDS Society</i> , 2021, 24, e25692.	1.2	20
8	A clinician's primer on epidemiology for COVID-19. <i>Med</i> , 2021, 2, 384-394.	2.2	1
9	Population density and basic reproductive number of COVID-19 across United States counties. <i>PLoS ONE</i> , 2021, 16, e0249271.	1.1	138
10	Individual- and Facility-Level Factors Associated with Facility Testing among Men in Malawi: Findings from a Representative Community Survey. <i>Diagnostics</i> , 2021, 11, 950.	1.3	2
11	Differentiated Service Delivery Models for HIV Treatment in Malawi, South Africa, and Zambia: A Landscape Analysis. <i>Global Health, Science and Practice</i> , 2021, 9, 296-307.	0.6	22
12	Getting resources to those who need them: the evidence we need to budget for underserved populations in sub-Saharan Africa. <i>Journal of the International AIDS Society</i> , 2021, 24, e25707.	1.2	1
13	Initial implementation of PrEP in Zambia: health policy development and service delivery scale-up. <i>BMJ Open</i> , 2021, 11, e047017.	0.8	19
14	Frequency of visits to health facilities and HIV services offered to men, Malawi. <i>Bulletin of the World Health Organization</i> , 2021, 99, 618-627.	1.5	18
15	Quality of life among people living with HIV in England and the Netherlands: a population-based study. <i>Lancet Regional Health - Europe</i> , 2021, 8, 100177.	3.0	13
16	Barriers to eliminating HIV transmission in England by 2030. <i>Lancet Public Health</i> , 2021, 6, e699-e700.	4.7	0
17	Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab040.	0.4	27
18	Economic evaluations of differentiated service delivery should include savings and ancillary benefits, not only health system costs: authors' reply. <i>Aids</i> , 2021, 35, 2235-2236.	1.0	0

#	ARTICLE	IF	CITATIONS
19	Changes in HIV treatment differentiated care uptake during the COVID-19 pandemic in Zambia: interrupted time series analysis. <i>Journal of the International AIDS Society</i> , 2021, 24, e25808.	1.2	8
20	Bringing Data Analytics to the Design of Optimized Diagnostic Networks in Low- and Middle-Income Countries: Process, Terms and Definitions. <i>Diagnostics</i> , 2021, 11, 22.	1.3	14
21	The cost effectiveness and optimal configuration of HIV self-test distribution in South Africa: a model analysis. <i>BMJ Global Health</i> , 2021, 6, .	2.0	2
22	Reproducible Science Is Vital for a Stronger Evidence Base During the COVID-19 Pandemic. <i>Geographical Analysis</i> , 2021, . .	1.9	0
23	The cost effectiveness and optimal configuration of HIV self-test distribution in South Africa: a model analysis. <i>BMJ Global Health</i> , 2021, 6, e005598.	2.0	9
24	Do differentiated service delivery models for HIV treatment in sub-Saharan Africa save money? Synthesis of evidence from field studies conducted in sub-Saharan Africa in 2017-2019. <i>Gates Open Research</i> , 2021, 5, 177.	2.0	5
25	Cost and Impact of Dried Blood Spot Versus Plasma Separation Card for Scale-up of Viral Load Testing in Resource-limited Settings. <i>Clinical Infectious Diseases</i> , 2020, 70, 1014-1020.	2.9	23
26	Novel metric for evaluating pre-exposure prophylaxis programme effectiveness in real-world settings. <i>Lancet HIV</i> , 2020, 7, e294-e300.	2.1	12
27	Economic evaluation of facility-based HIV self-testing among adult outpatients in Malawi. <i>Journal of the International AIDS Society</i> , 2020, 23, e25612.	1.2	13
28	Cost-effectiveness of adoption strategies for point of care HIV viral load monitoring in South Africa. <i>EClinicalMedicine</i> , 2020, 28, 100607.	3.2	17
29	Retention in care and viral suppression in differentiated service delivery models for HIV treatment delivery in sub-Saharan Africa: a rapid systematic review. <i>Journal of the International AIDS Society</i> , 2020, 23, e25640.	1.2	72
30	Pre-treatment HIV drug resistance testing cost-effectiveness. <i>EClinicalMedicine</i> , 2020, 22, 100381.	3.2	0
31	Effect of facility-based HIV self-testing on uptake of testing among outpatients in Malawi: a cluster-randomised trial. <i>The Lancet Global Health</i> , 2020, 8, e276-e287.	2.9	64
32	Managing multidrug-resistant tuberculosis in South Africa: a budget impact analysis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 376-382.	0.6	13
33	Ending the HIV epidemic in the USA. <i>Lancet HIV</i> , 2020, 7, e454-e455.	2.1	4
34	Point-of-care assays for early infant diagnosis in Zimbabwe. <i>Lancet HIV</i> , 2019, 6, e146-e147.	2.1	1
35	Monitoring viral load for the last mile: what will it cost?. <i>Journal of the International AIDS Society</i> , 2019, 22, e25337.	1.2	29
36	Optimizing viral load testing access for the last mile: Geospatial cost model for point of care instrument placement. <i>PLoS ONE</i> , 2019, 14, e0221586.	1.1	28

#	ARTICLE	IF	CITATIONS
37	Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men. PLoS ONE, 2019, 14, e0210179.	1.1	32
38	Targeted HCV core antigen monitoring among HIV-positive men who have sex with men is cost-saving. Journal of Virus Eradication, 2019, 5, 179-190.	0.3	4
39	Differentiated models of service delivery for antiretroviral treatment of HIV in sub-Saharan Africa: a rapid review protocol. Systematic Reviews, 2019, 8, 314.	2.5	19
40	Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study. Journal of the International AIDS Society, 2019, 22, e25427.	1.2	20
41	Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058. Eurosurveillance, 2019, 24, .	3.9	21
42	Targeted HCV core antigen monitoring among HIV-positive men who have sex with men is cost-saving. Journal of Virus Eradication, 2019, 5, 179-190.	0.3	1
43	Cardiovascular Disease Prevention Policy in Human Immunodeficiency Virus: Recommendations From a Modeling Study. Clinical Infectious Diseases, 2018, 66, 743-750.	2.9	22
44	Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study. Lancet HIV,the, 2018, 5, e146-e154.	2.1	61
45	Impact of a borderless sample transport network for scaling up viral load monitoring: results of a geospatial optimization model for Zambia. Journal of the International AIDS Society, 2018, 21, e25206.	1.2	23
46	Evaluating the integration of HIV self-testing into low-resource health systems: study protocol for a cluster-randomized control trial from EQUIP Innovations. Trials, 2018, 19, 498.	0.7	13
47	Methodological concerns regarding a PrEP model – Authors' reply. Lancet Infectious Diseases, The, 2017, 17, 482-483.	4.6	0
48	Cost-effectiveness of early identification of HIV infection. Lancet HIV,the, 2017, 4, e431-e432.	2.1	0
49	Non-targeted HIV screening in emergency departments in the Netherlands. Netherlands Journal of Medicine, 2017, 75, 386-393.	0.6	5
50	Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study. Lancet Infectious Diseases, The, 2016, 16, 1423-1429.	4.6	89
51	Partner Notification for Reduction of HIV-1 Transmission and Related Costs among Men Who Have Sex with Men: A Mathematical Modeling Study. PLoS ONE, 2015, 10, e0142576.	1.1	14
52	Sustainable HIV treatment in Africa through viral-load-informed differentiated care. Nature, 2015, 528, S68-S76.	13.7	141
53	Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study. Journal of the International AIDS Society, 2014, 17, 19164.	1.2	26
54	Cost-Effectiveness of PrEP in HIV/AIDS Control in Zambia. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 221-228.	0.9	25

#	ARTICLE	IF	CITATIONS
55	Spinal cord injury in the emergency context: review of program outcomes of a spinal cord injury rehabilitation program in Sri Lanka. <i>Conflict and Health</i> , 2014, 8, 4.	1.0	8
56	Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. <i>The Lancet Global Health</i> , 2014, 2, e23-e34.	2.9	188
57	Averted HIV infections due to expanded antiretroviral treatment eligibility offsets risk of transmitted drug resistance. <i>Aids</i> , 2014, 28, 73-83.	1.0	24
58	Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa. <i>Aids</i> , 2013, 27, 2943-2951.	1.0	61
59	Cost-Effectiveness of Pre-Exposure Prophylaxis (PrEP) in Preventing HIV-1 Infections in Rural Zambia: A Modeling Study. <i>PLoS ONE</i> , 2013, 8, e59549.	1.1	40
60	HIV Treatment as Prevention: Models, Data, and Questions—Towards Evidence-Based Decision-Making. <i>PLoS Medicine</i> , 2012, 9, e1001259.	3.9	64
61	Density of Drinking Establishments and HIV Prevalence in a Migrant Town in Namibia. <i>AIDS and Behavior</i> , 2012, 16, 829-834.	1.4	10
62	HIV testing and antiretroviral treatment strategies for prevention of HIV infection: impact on antiretroviral drug resistance. <i>Journal of Internal Medicine</i> , 2011, 270, 532-549.	2.7	14
63	Assessing fitness-for-purpose and comparing the suitability of COVID-19 multi-country models for local contexts and users. <i>Gates Open Research</i> , 0, 5, 79.	2.0	1
64	Do differentiated service delivery models for HIV treatment in sub-Saharan Africa save money? Synthesis of evidence from field studies conducted in sub-Saharan Africa in 2017-2019. <i>Gates Open Research</i> , 0, 5, 177.	2.0	1